# References — BPC-157 + TB-500 blend research — Wolverine Clinic

> Full citation list for the BPC-157 + TB-500 (Wolverine) blend research summary: PubMed and PubMed Central links, DOIs, journal references for every claim on the site.

DOI and PubMed link for each citation. Numbered to match the inline markers throughout the site.

## How this list is built

Every numeric citation marker in the body of this site — `[1]`, `[2]`, and so on — corresponds to one of the entries below. The list is sorted in citation order, not alphabetically. Each entry carries the title, authors, journal, year, DOI, PubMed identifier where available, and a direct link to the open-source full text or the PubMed listing.

The references are split between two compound bodies: the BPC-157 preclinical and review literature (entries 1–8 and 16–17, 19), and the thymosin beta-4 / TB-500 preclinical and clinical literature (entries 9–15). Entry 18 is the published mechanism commentary on the BPC-157 + TB-500 combination specifically.

All entries link to publicly accessible records on PubMed, PubMed Central, or the open-access publisher page. None of the links are to commercial vendor sites; none of the sources cited is a vendor publication.

## Notes on the evidence base

Several characteristics of the underlying literature are worth noting before reading the list:

— The BPC-157 preclinical record is dominated by work from a single research group (Sikiric / Seiwerth in Zagreb). Independent replication outside that group is comparatively sparse.

— Most of the thymosin beta-4 mechanism and outcome data are on the full-length 43-amino-acid parent peptide, not on the 7-amino-acid LKKTETQ fragment (TB-500) sold for research.

— Human clinical data for BPC-157 are limited to three published pilot studies; for thymosin beta-4 they include Phase 2 dermal trials, a Phase 2 dry-eye trial, and a Phase 3 ophthalmic trial in neurotrophic keratopathy.

— No controlled in-vivo study of the BPC-157 + TB-500 blend versus either monotherapy has been published.

The full citation list follows in the assembler's rendering of `references_index` below.

## References

[1] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006. https://pubmed.ncbi.nlm.nih.gov/16583442/
[2] Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. https://pubmed.ncbi.nlm.nih.gov/20225319/
[3] Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today. 2008. https://pubmed.ncbi.nlm.nih.gov/18668315/
[4] Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/
[5] Chang CH, Tsai WC, Hsu YH, Pang JS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
[6] Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World Journal of Gastroenterology. 2017;23(48):8465. https://pubmed.ncbi.nlm.nih.gov/29358856/
[7] Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006. https://pubmed.ncbi.nlm.nih.gov/17186181/
[8] Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC 157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sciences. 2004. https://pubmed.ncbi.nlm.nih.gov/15531385/
[9] Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. https://pubmed.ncbi.nlm.nih.gov/15565145/
[10] Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. https://pubmed.ncbi.nlm.nih.gov/17108969/
[11] Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2907184/
[12] Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004. https://pubmed.ncbi.nlm.nih.gov/15037013/
[13] Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, Orgel A, Kleinman HK, Elkin M. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. 2004. https://pubmed.ncbi.nlm.nih.gov/14657002/
[14] Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. International Journal of Molecular Sciences. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
[15] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a Phase 2 randomized trial. Cornea. 2015. https://pubmed.ncbi.nlm.nih.gov/25826322/
[16] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
[17] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025. https://www.mdpi.com/1424-8247/18/2/185
[18] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P (reply); Sikiric P et al. (comment). Reply to Sikiric et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Comment on Jozwiak et al. Pharmaceuticals. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12567171/
[19] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://doi.org/10.1177/15563316251355551
[20] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute. 2003. https://pubmed.ncbi.nlm.nih.gov/14625258/
[21] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[22] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[23] Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012. https://pubmed.ncbi.nlm.nih.gov/23084823/
[24] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[25] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[26] et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/34346165/
[27] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017. https://pubmed.ncbi.nlm.nih.gov/27847966/

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.